Geographic regionsAll regions contributed to the solid growth in the third quarter of 2012. The Asia-Pacific / Japan region (19% of net sales, +14% CER) delivered double-digit CER sales growth in the Molecular Diagnostics, Applied Testing and Pharma customer classes. In the Americas (47% of net sales, +11% CER), higher sales of the QuantiFERON latent TB test and Personalized Healthcare products were among the drivers. The Europe / Middle East / Africa region (33% of net sales, +7% CER) advanced on growth contributions from many northern European countries as well as Russia and Turkey.
QIAGEN Reports Third Quarter 2012 Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.